DOLPHIN Vagus Stimulation Receives Health Canada Approval for Covid-19 (ARDS)Consumer
enter for Pain & Stress Research Ltd., a bio-electronic medical research company, today announced that its Dolphin Vagal Stim device has received breakthrough approval from Health Canada as Canada’s first therapy for treating COVID-19.
There is one therapy quietly saving thousands of COVID lives, and it approved by Health Canada for COVID-19 acute respiratory distress. It is called Dolphin Vagal Stimulation. The vagus nerve is the longest nerve in the body that travels down from the brain to innervate and control breathing, stress levels and inflammation. The Vagus nerve is considered the "brakes" of our bodies, controlling 80% of our parasympathetic response.
“Dolphin Vagal Nerve Stimulator (VNS) Kit retails for $749.00 USD“
Dolphin Vagal Nerve Stimulator is now authorized by Health Canada for emergency use authorization for acute use at home or in a healthcare setting to treat adult patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow, and for whom approved pharmacologic therapies are not tolerated or provide insufficient symptom relief as assessed by their healthcare provide. Order # 327574
Company spokesperson Yulia Kramarenko states that "as North American COVID-19 related deaths reach more than 1.3 million casualties, knowledge of this effective, safe & approved COVID-19 therapy MUST be shared with both health care professionals and the public".
Dolphin Vagal Nerve Stim Applications:
PREVENTION: Dolphin may be applied preventatively to friends, family members or front-line workers in order to enhance vagal tone & improve immunity. (Home application timeSee all the latest jobs in Consumer